Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 313
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT07308574 | Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS | ||
| NCT01488097 | Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency | ||
| NCT02605993 | Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT01193348 | An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome | ||
| NCT04730804 | A Study of ALXN1830 in Healthy Adult Participants | ||
| NCT01307098 | Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency | ||
| NCT04512235 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) | ||
| NCT07218887 | ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy | ||
| NCT02293408 | Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB | ||
| NCT03551743 | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4) | ||
| NCT04982289 | Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis | ||
| NCT01358370 | A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype | ||
| NCT07037420 | ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly | ||
| NCT00380159 | Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A | ||
| NCT04980248 | Study of ALXN1850 in Participants With Hypophosphatasia (HPP) | ||
| NCT07221838 | A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab | ||
| NCT02987504 | Study of Samalizumab in Patients With Advanced Cancer | ||
| NCT01205152 | Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP) | ||
| NCT05274633 | Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria | ||
| NCT05565092 | Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease | ||
| NCT03075878 | A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA) | ||
| NCT05389449 | A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH | ||
| NCT02596100 | A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations | ||
| NCT01229254 | Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter | ||
| NCT02376751 | An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency | ||
| NCT02013037 | The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation | ||
| NCT04709081 | A Drug Interaction Study of ACH-0145228 | ||
| NCT03397888 | The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist | ||
| NCT04320602 | Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab | ||
| NCT05780645 | A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants | ||
| NCT01892345 | A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) | ||
| NCT05259085 | Study of ALXN2050 in Participants With Hepatic Impairment | ||
| NCT01194973 | An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome | ||
| NCT01522183 | Atypical Hemolytic-Uremic Syndrome (aHUS) Registry | ||
| NCT06830798 | Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation | ||
| NCT07157787 | Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) | ||
| NCT05047484 | A Study of Multiple Doses of ALXN2050 in Healthy Adults | ||
| NCT03766347 | Pediatric NMOSD Observational Study | ||
| NCT00375609 | Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT) | ||
| NCT00670774 | Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant | ||
| NCT02618512 | A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously | ||
| NCT04202341 | Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) | ||
| NCT04256148 | ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia | ||
| NCT06578949 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT04195763 | Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa) | ||
| NCT01095887 | Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation | ||
| NCT01895127 | Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation | ||
| NCT00935883 | Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) | ||
| NCT01716728 | Identification of Undiagnosed Lysosomal Acid Lipase Deficiency | ||
| NCT00844428 | Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS |
